Soyselect^® has been tested in three different clinical trials at dosages ranging from 400 to 640 mg/day, to evaluate its efficacy in the management of menopause-related symptoms.

The overall figure of the effects of Soyselect^® can be summarized as follow:

Vasomotor symptoms relief in post-menopausal women (400 mg/day) (1,2):

a double-blind randomized pilot study has been performed to comparatively evaluate, on 39 postmenopausal women, the activity of Soyselect^® and placebo on early climacteric symptoms, with a significative reduction of the number of hot flushes (-45% after 5 weeks of treatment with Soyselect^®, chart 1).

another double-blind, randomized, parallel group, outpatient, multicenter (15 sites) study has been performed on 177 postmenopausal women, with a significative reduction of incidence and severity of hot flushes (-32% at week 10) and number of awakenings due to night sweats (-62% at week 12, chart 2).



Improvement of cognitive function in older women (640 mg/day) (3):

a 6-month, double-blind, randomized, placebo-controlled clinical trial has been performed on 56 postmenopausal women. The postmenopausal women treated with Soyselect^® did consistently better, both in comparison with their own baseline scores and with the placebo group responses at 6 months (chart 3).

(1) Scambia G., Mango D., Signorile P.G., Anselmi Angeli R., Palena C., Gallo D., Bombardelli E., Morazzoni P., Riva A., Mancuso S., Menopause 7,105 (2000)
(2) Upmalis D.H., Lobo R., Bradley L., Warren M., Cone F.L., Lamia C.A., Menopause 7, 236 (2000).
(3) Kritz-Silverstein D., Von Mühlen D., Barrett-Connor E., Bressel M.A.B., Menopause 10, 196 (2003).